Longevity Biotech Pitch Night by the Longevity Investors Network
When: October 22, 2025 · Wightman Mansion, Boston
October 17th RSVP Deadline. This is a limited capacity event, please RSVP by October 17th to secure your ticket!
About the Event
Join us for an exclusive evening at the historic Wightman Mansion in Boston as we showcase some of the most promising longevity startups shaping the future.
Seven handpicked companies will take the stage to share their vision, scientific breakthroughs, and growth potential in front of a curated audience of leading investors. This is a unique opportunity to get a first look at innovative ventures before they make their mark.
What to Expect
✨ 7 Startup Pitches – Hear directly from founders building the next big thing in Longevity.
🤝 Investor-Only Access – An intimate, invite-only setting designed for meaningful connections.
🏛 Iconic Venue – Network and discover new ideas at the elegant Wightman Mansion.
🍷 Networking Reception – Enjoy light bites and drinks while connecting with founders and fellow investors.
Agenda
3:00 PM - 3:55 PM: Registration / Networking
3:55 PM - 4:00 PM: Keith Comito Opening Remarks
4:00 PM - 4:20 PM: Pitch Presentation #1
4:20 PM - 4:40 PM: Pitch Presentation #2
4:40 PM - 5:10 PM: Break / Networking
5:10 PM - 5:20 PM: Remarks from the CEO - Lifespan Research Institute (Keith Comito)
5:20 PM - 5:30 PM: Pitch Presentation #4
5:30 PM - 5:40 PM: Pitch Presentation #5
5:40 PM - 5:50 PM: Pitch Presentation #6
5:50 PM - 6:00 PM: Pitch Presentation #7
Who’s Pitching
BioIO: BIOIO is a therapeutics company developing first-in-class gerotherapies for conditions like T2DM. Lead program BIOIO-1001 is a potent insulin sensitizer that increases NAD+ via the NMNAT-Sirt3 axis. BIOIO-1001 has strong efficacy in diverse models of diabetes where it also improves body composition and reduces cardiovascular risk. It is expected to enter the clinic in H1 2027. BIOIO-2001’s MoA centers on the emerging longevity target, SPT. Both assets emerged from our Mechanism of Action Technologies (MOAT) platform. MOAT flips rationale drug design on its head by first focusing on the best chemistry that could yield a multi-indication therapy.
XM Therapeutics: Developing novel therapies to repair the Extracellular Matrix. Harnessing the healing power of our body's natural intercellular network to treat chronic diseases and promote healthy organs.
Hayflick Partners: Development stage company that is leveraging new scientific discoveries in aging biology to address specific health and aesthetic concerns associated with declining cellular function. Our research team includes experts in the study of rapamycin and its efficacy across a variety of clinical settings. Our flagship investigational product is a low-dose topical therapeutic agent that is designed to deliver the healthspan benefits of rapamycin while minimizing systemic exposure.
Maxwell Biosciences: Maxwell is a biotechnology company focused on developing novel anti-infective therapeutics using a platform called CLAROMER®. These are synthetic small molecule (peptoid-mimic) agents that imitate parts of the body’s innate immune peptides but aim to be more stable, non-peptide, easier to deliver, etc. Their drug candidates are intended to target a broad spectrum of pathogens — viruses, bacteria, fungi, biofilms — with the goal of combating drug resistance, pandemics, and infections in general.
Vasa Therapeutics: Vasa is a preclinical/clinical-stage biotech company that develops therapies targeting cardiovascular aging. Their mission involves treating conditions linked to the aging heart and circulatory system — for example, heart failure with preserved ejection fraction (HFpEF) and related disorders. One of their lead compounds is VS-041, an oral small molecule that in preclinical models reduces cardiac fibrosis and modifies biomarkers implicated in worse outcomes. They’ve conducted a Phase 1 clinical trial (first in humans) for VS-041, showing safety and tolerability, and plan further trials.
Adiso Therapeutics: At Adiso, we create medicines to treat inflammatory diseases, to improve the lives of patients and their families. We believe that current therapeutic approaches are often inadequate to halt disease progression or run the risk of burdening the patient with significant safety concerns. To tackle these challenges, we are advancing an innovative pipeline of multi-modal agents all with novel mechanisms of action and a precision therapeutic approach.
Event Details
📅 Date: Wednesday, October 22, 2025
📍 Location: Wightman Mansion, Boston
🎟 Audience: Invite-only for investors
🤝 INVESTOR ATTENDEES:
Investors From: Longevity Investor Network, Longevity Vision Fund, HanuVentures, Longrun Ventures, SOS Ventures, Maximon, Quadrascope, DraperVC, Juvenescence, CambrianBio, LongeVC, Methuselah Foundation, 1004 Ventures, Moonstone Venture Capital, CurieBio, Centenarian Fund, Formic Ventures, Prime Movers Lab, Unruly Capital, Life Science Angels, Emerging Longevity Ventures, BoxOne Ventures, Kaiser Pernamente Ventures, OrbiMed, IndieBio, Apollo Health Ventures, Age1, LongevityTechFund and more
Register Your Interest
If you’ve received an invitation, please RSVP to confirm your spot. Space is limited.
Lifespan Research Institute (“LRI”) is a 501(c)(3) nonprofit organization focused on the defeat of age-related disease and the extension of healthy human lifespan – through raising funds and awareness for scientific work addressing the root causes of the aging process, building a thriving ecosystem of mission aligned stakeholders which can be mobilized to strategic action, and spearheading relevant research projects directly. We work to identify, develop, and promote initiatives with outsized impact and the greatest potential to realize widespread access to regenerative medicine solutions targeting the disabilities and diseases of aging.
Lifespan.io Sponsors & Members of the Lifespan Alliance
We are deeply honored by and grateful for the support of our Lifespan Alliance members, whose contributions are integral to our mission to extend healthy human lifespan and overcome age-related disease. These forward-thinking organizations empower our work at the forefront of scientific discovery and advocacy, advancing transformative interventions and fostering breakthroughs that will redefine health and aging for generations to come. Join the Lifespan Alliance today.
The Longevity Investor Network is an initiative of Lifespan Research Institute, a 501(c)(3) nonprofit formed through the merger of SENS Research Foundation and Lifespan.io.
As a 501(c)3 nonprofit, your support is vital to our mission at LRI—consider making a donation to help us continue advancing longevity science and hosting impactful events like this one.
For more information on how to join the Longevity Investor Network, please reach out to [email protected]
This (free & investor invite only) dedicated pitch session event will take place at the same location and concurrently with Longevity Biotech 2025 — a leading longevity drug development conference (paid ticketed event)